A new regenerative medicine can heal the front of the eye in as little as two days after surgery by stimulating faster tissue repair, according to a new study.
Uncategorized
Treat-and-extend therapy with Eylea for AMD improves vision, reduces injections over 2 years
LAS VEGAS — Two-year results of the ATLAS study showed visual and anatomic improvements in eyes with neovascular age-related macular degeneration treated with a treat-and-extend program using Eylea. “The treat-and-extend program has never been validated with aflibercept [Eylea, Regeneron] to date, and given the molecular differences of anti-VEGF drugs and the potential greater durability effect for aflibercept, my colleagues and I designed and conducted the ATLAS study,“ Carl D. Regillo, MD, FACS, said at the American Academy of Ophthalmology annual meeting.
Uncategorized
Consider age, residual stromal bed, percent tissue altered to improve accuracy of screening for ectasia risk
LAS VEGAS — Using the weighted equation of age, residual stromal bed and percent tissue altered may improve the efficacy of screening ectasia risk in patients with normal topography who undergo LASIK, according to a study presented here. “The purpose of this study was to specifically develop an ectasia risk equation considering percent tissue altered, flap percentage, residual stromal bed, ablation depth, and age all together to have a combination that would provide very high sensitivity, and with the other parameters, we would increase the specificity of our findings,” Marcony R. Santhiago, MD, said at the American Academy of Ophthalmology annual meeting.
Uncategorized
Surgical, medical treatments for squamous neoplasia both have pros, cons
LAS VEGAS — Ocular surface squamous neoplasia is one of the most common nonpigmented tumors of the ocular surface, and there is much debate regarding which treatment to choose, according to a presentation here. At the American Academy of Ophthalmology annual meeting, Carol L. Karp, MD, weighed the pros and cons of excision alone with a no-touch technique and of treatment with chemotherapeutic agents such as mitomycin C, 5-fluorouracil (5-FU) and interferon-alpha-2b.
Uncategorized
Alphaeon acquires Lensar, partners with PhysIOL to commercialize trifocal IOL technology
LAS VEGAS — Alphaeon has entered into a definitive agreement to acquire Lensar for an estimated $59 million in cash, stock and assumed debt, the company announced in a press release. “We’re excited with the chance to join Alphaeon, and together leverage our proprietary platform technology to develop new clinical innovations benefiting physicians and patients alike,” Nick Curtis, CEO of Lensar said in the release.
Uncategorized
Speaker: Bilateral, same-day cataract surgery poses no additional risk to patients
LAS VEGAS — Bilateral, same-day cataract surgery should not pose any additional undue risks to the patient than sequential cataract surgery, according to a presentation here.“Bilateral, same-day cataract surgery offers convenience and time saving for patients through reduced time off work, fewer appointments, less travel and concurrent recovery of eyes. Costs savings may also be realized to payers, employers and employees,” Neal H. Shorstein, MD, said at the American Academy of Ophthalmology annual meeting.